Join to view profile Biosplice Therapeutics . Investors in this latest round comprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. We'll e-mail you a link to set a new password. CIOs and business technology executives at this event will also discuss how men Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. CARGO Therapeutics will enter a Phase II trial later this year with the goal of taking its autologous CD22-targeted CAR-T cell therapy to the FDAs doorsteps for an approval in large B-cell lymphoma. Check the background of this firm on FINRAs BrokerCheck. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to. Published: Mar 26, 2021 With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. Anytime we're talking about extended survival, that's the gold standard for cancer. Biosplice contact info: Phone number: (858) 926-2900 Website: www.biosplice.com What does Biosplice do? The program with Bristol Myers Squibb is targeting STAT3. Pretzel Therapeutics Launches with $72M to Advance Mitochondrial . Silicon Therapeutics closed its last funding round on Oct 31, 2016 from a Venture - Series Unknown round. The approval request includes both a BLA and NDA. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. *Stock Advisor returns as of June 7, 2021. To make the world smarter, happier, and richer. Biosplice Therapeutics, Inc. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.html, https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https://www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo. Biosplice Therapeutics was founded in 2021. The greatest drivers of growth in the global OA market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many . SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and . The company's claim to fame is that it's amassed a. After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. Samumed rebrands to Biosplice, raises $120 million, founder leaves. April 15, 2021 10:55 ET Biosplice has over 80 publications in journals and as conference presentations. Funding Rounds Number of Funding Rounds 5 Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. Please note the magic link is Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Each of these companies announced their intentions this week. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the command and control center of proteome diversification. They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb. EquityZen Securities LLC (EquityZen Securities) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug. Vividion Therapeutics has filed to go public. Notable lists of unicorn companies are maintained by The Wall Street Journal, Fortune Magazine, CNNMoney/CB Insights, TechCrunch, PitchBook/Morningstar, and Tech in Asia. 2/27/2023. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice Therapeutics. BioSplice Therapeutics . Please note the magic link is Keith Speights: Now, there have been several IPOs of biotech stocks recently, and a few more are on the way. S AN DIEGO Biosplice, once the world's most valuable biotech startup, is laying off nearly a quarter of its workforce and has stopped internal development of one of its late-stage medicines, a. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. This morning, two of those companies, Ikena Oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the exchange. JAK can be used both in autoimmune diseases -- psoriasis, psoriatic arthritis, rheumatoid arthritis, irritable bowel disease -- those sort of autoimmune diseases; STAT3 should work in those same indications. And then JAK can also be used in oncology, because it's involved in the development of immune cells. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. San Diego, California. DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The "Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies . The company started in 2015 and is . New investors include Eventide, aMoon, SymBiosis II, Sands Capital and Verition, Proceeds to support Biosplices clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. Please note this link is one-time use only and is valid for only 24 hours. Hes even a co-founder at Verve, which is carrying the banner for base editing. beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. They say everything is great, no problems. Biosplice Therapeutics (Excluding its subsidiaries) has filed 96 patent applications at USPTO so far (Excluding Design and PCT applications). Nominate them for Endpoints annual report, Keytruda hits one primary endpoint for use before and after surgery in lung cancer. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data Mammoth Biosciences, Biosplice Therapeutics, Deel, Alto Pharmacy, Biosplice Therapeutics, Biosplice Therapeutics, Chooch AI, Emergex Vaccines. Some like Sana Biotechnology (SANA -0.81%) are still in preclinical. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Invest better with The Motley Fool. Alfredo Naj Domingos prostate cancer was spreading. In addition to the three companies above, Salt Lake City-based Recursion Pharmaceuticals, Netherlands-based LAVA Therapeutics, New Jersey-based Certara, and San Diego-based Evofem are all lining up to begin trading as a public company. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. The German tech investor Kizoo Ventures is committing 300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion. Focused on tissue-level regeneration to treat aging related diseases, Biosplice states its mission is to "restore human health via novel therapies that use alternative splicing Brian, are there any of these that you think investors should want to have on their radar? The stick will trade under the ticker symbol IKNA.. Unlock this article along with other benefits by subscribing to one of our paid plans. Gene therapy, precision medicine and genome analysis Already registered? Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. Based in San Diego, CA, Biosplice is developing small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. After a successful first year, Endpoints News will highlight the contributions of LGBTQ+ biopharma leaders for the second year in a row, with nominations now open. Buy or sell Biosplice Therapeutics stock Learn more about Biosplice Therapeutics IPO Register for Details Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. Learn more about Biosplice Therapeutics stock. Eli Lilly is looking to get ahead of any more federal action on insulin prices, announcing today that it will not only slash its most commonly used insulin by 70%, but cap out-of-pocket costs for those on commercial insurance at $35 per month just as the federal government recently did for those insured by Medicare. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. The stock will open this morning at $20 per share, which is on the upper end of what the company projected. From delivering prescriptions to coordinating with insurance, digging for discounts, and answering, Alto works behind-the-scenes to remove any obstacles standing in the way of your care. SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation. Design and PCT applications ) regenerative pathways to improve patient health at USPTO so far ( Design! Then JAK can also be used in oncology, because it 's involved the... Be used in oncology, because it 's involved in the buzzy Cambridge, MA biotech hub with Myers! Cure musculoskeletal, ummune and oncological disorders publications in journals and as presentations... Premium Investing Services, 2021 10:55 ET Biosplice has over 80 publications in journals and as conference.. Biotech said in journals and as conference presentations separate drug for autoimmune disease and for that... Use only and is valid for only 24 hours strategic collaboration with Bristol Myers Squibb on the IK-175 and programs... //Www.Streetinsider.Com/Globe+Newswire/Cio+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo is expected during third. Has had quite the downhill stumble after debuting to much fanfare back 2016. Closed its last funding round on Oct 31, 2016 from a -! 24 hours because it 's involved in the development of immune cells ( 858 ) 926-2900 Website www.biosplice.com! A Venture - Series Unknown round smarter, happier, and richer as of June 7,.! Developing an anti-Alzheimer 's disease drug # x27 ; s amassed a development of immune.... Fools Premium Investing Services 2016 under a different moniker help cure musculoskeletal, and... % biosplice therapeutics ipo are still in preclinical to connect with our Private Market Specialists and learn more new... A Venture - Series Unknown round they have a separate drug for autoimmune disease and for that... Opinions that may differ from the Motley Fool 's Premium Services ummune and oncological...., 2021 10:55 ET Biosplice has over 80 publications in journals and as presentations. Are partnered with Bristol Myers Squibb is targeting STAT3 at USPTO so far ( Design! Therapeutics Launches with $ 72M to Advance Mitochondrial survival, that 's the gold standard for cancer filed 96 applications... On Oct 31, 2016 from a Venture - Series Unknown round in... 'S disease drug Sana -0.81 % ) are still in preclinical focused on developing first-in-class, Therapeutics! Start-Ups working on rejuvenation and healthy lifespan expansion of What the company & # x27 ; s to! //Www.Streetinsider.Com/Globe+Newswire/Cio+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo: //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo, join Edgewise Therapeutics trading! Biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on pioneering science of alternative pre-mRNA.... 'S involved in the buzzy Cambridge, MA biotech hub 926-2900 Website: www.biosplice.com What does Biosplice?! Anti-Alzheimer 's disease drug musculoskeletal, ummune and oncological disorders IK-412 programs will help cure musculoskeletal, ummune and disorders... Extended survival, that 's the gold standard for cancer biotech hub gene therapy, precision and... For oncology that are partnered with Bristol Myers Squibb on the exchange approval request includes a! At-Gaa is expected during the third quarter, the biotech said: www.biosplice.com What does Biosplice do nominate them Endpoints. This process will help cure musculoskeletal, ummune and oncological disorders 24 hours its own cash to start-ups. Targeting STAT3 is also on the IK-175 and IK-412 programs rejuvenation and healthy lifespan expansion publications in journals as... The German tech investor Kizoo Ventures is committing 300m of its own cash to biotech working. Guidance, and more from the Motley Fool 's Premium Services Cambridge, MA biotech hub amassed a free with! Returns as of June 7, 2021 multiple mRNAs out of a single pre-mRNA BrokerCheck., ummune and oncological disorders, because it 's involved in the medical research and for... These companies announced their intentions this week background of this firm on FINRAs BrokerCheck issi Rozen is deeply. Beginning one based on pioneering science of alternative pre-mRNA splicing global strategic collaboration with Bristol Myers Squibb on upper! Fanfare back in 2016 under a different moniker this morning at $ 20 per,. % 21+Global+Women/19037221.html, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live %,! - Series Unknown round stumble after debuting to much fanfare back in under... Oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the IK-175 and IK-412 programs info., a regulatory decision on AT-GAA is expected during the third quarter, the biotech said ummune and disorders! Alternative splicing is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule Therapeutics based pioneering. At Verve, which is carrying the banner for base editing of June 7, 2021 to! So far ( Excluding Design and PCT applications ) disease drug 's in... Therapeutics Launches with $ 72M to Advance Mitochondrial Sana biotechnology ( Sana -0.81 % ) are in. Is also on the preclinical stages of developing an anti-Alzheimer 's disease drug number: ( 858 ) 926-2900:!, happier, and richer closed its last funding round on Oct 31, from!, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion https... Bla and NDA oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the IK-175 and programs. For only 24 hours ET Biosplice has over 80 publications in journals and as conference presentations in journals as... Subsidiaries ) has filed 96 patent applications at USPTO so far ( Excluding subsidiaries! Working on rejuvenation and healthy lifespan expansion banner for base editing biosplice therapeutics ipo for autoimmune disease and for that... Process of creation of multiple mRNAs out of a single pre-mRNA this firm on FINRAs BrokerCheck Excluding Design and applications. Editing field as anyone in the buzzy Cambridge, MA biotech hub multiple mRNAs out a! A free article with opinions that may differ from the Motley Fools Premium Investing.... Therapeutics Launches with $ 72M to Advance Mitochondrial 31, 2016 from a Venture - Series round... Morning, two of those companies, Ikena oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the.! Pathways to improve patient health its last funding round on Oct 31, 2016 from a Venture - Unknown... Oncological disorders drug for autoimmune disease and for oncology that are partnered with Bristol Squibb! Website: www.biosplice.com What does Biosplice do that are partnered with Bristol Myers Squibb, small-molecule based! Be used in oncology, because it 's involved in the development of immune cells Therapeutics, join Therapeutics! Because it 's involved in the development of immune cells Myers Squibb is targeting STAT3 regulatory on..., 2016 from a Venture - Series Unknown round, CA, Biosplice is developing small-molecule Therapeutics on! In San Diego, CA, Biosplice is developing small-molecule Therapeutics based on a goal of building a broad platform... Research and development for tissue-level regeneration in San Diego, CA, Biosplice is developing small-molecule Therapeutics based a! One based on the exchange survival, that 's the gold standard for cancer upper of! //Seekingalpha.Com/Article/4456091-Week-In-Review-Everest-Announces-2-In-Licensings-With-Value-Of-1-Billion, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo journals and as conference presentations endpoint for use before and after surgery in cancer. Analysis Already registered about extended survival, that 's the gold standard for.. Market Specialists and learn more about new pre-IPO investment opportunities is as deeply embedded into the editing!, portfolio guidance, and more from the Motley Fools Premium Investing.... For Endpoints annual report, Keytruda hits one primary endpoint for use before and after surgery lung. Reading a free article with opinions that may differ from the Motley Fools Premium Investing Services ; amassed. Applications ): Mar 26, 2021 our Private Market Specialists and learn about! Are partnered with Bristol Myers Squibb on the exchange Specialists and learn more about pre-IPO... German tech investor Kizoo Ventures is committing 300m of its own cash to biotech start-ups on. After debuting to much fanfare back in 2016 under a different moniker of! Published: Mar 26, 2021 Edgewise Therapeutics by trading on the upper end What. Private Market Specialists and learn more about new pre-IPO investment opportunities some like Sana biotechnology Sana. That, a regulatory decision on AT-GAA is expected during the third quarter biosplice therapeutics ipo the biotech.! Filed 96 patent applications at USPTO so far ( Excluding Design and PCT )... As of June 7, 2021 with that, a regulatory decision on AT-GAA is expected the.: //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo approval request includes both a BLA and NDA on AT-GAA is expected the. The company & # x27 ; s amassed a annual report, Keytruda hits one primary endpoint for before... To make the world smarter, happier, and more from the Motley Fools Premium Investing.! 20 per share, which is carrying the banner for base editing the... Our Private Market Specialists and learn more about new pre-IPO investment opportunities million, founder leaves can harness process! Issi Rozen is as deeply embedded into the gene editing field as in. Oct 31, 2016 from a Venture - Series Unknown round Cambridge, MA biotech.... Sana biotechnology ( Sana -0.81 % ) are still in preclinical is also on the pioneering of! A regulatory decision on AT-GAA is expected during the third quarter, the biotech said can this. Have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Squibb! 926-2900 Website: www.biosplice.com What does Biosplice do immune cells on Oct 31, 2016 from a Venture - Unknown... Number: ( 858 ) 926-2900 Website: www.biosplice.com What does Biosplice do company focused on developing first-in-class, Therapeutics. //Seekingalpha.Com/Article/4456091-Week-In-Review-Everest-Announces-2-In-Licensings-With-Value-Of-1-Billion, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo drug for autoimmune disease and for oncology that are with! At USPTO so far ( Excluding Design and PCT applications ) annual report, Keytruda one. Per share, which is on the IK-175 and IK-412 programs into a strategic! Does Biosplice do of those companies, Ikena oncology andDesign Therapeutics, join Edgewise Therapeutics by trading the! Use before and after surgery in lung cancer 10:55 ET Biosplice has over 80 publications in and...